Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ferumoxytol MRI Mapping in Glioblastoma
NCT02359097Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2015
- Primary completion
- Mar 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ferumoxytol in glioblastoma (GBM), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Assessment of overlay accuracy with 3-dimensional anatomical T1w post contrast scans, Confidence in identifying the lesion corresponding areas on cerebral blood volume maps and 2 more. Started Jan 2015; status: completed.
02
Drugs
ferumoxytol
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02359097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359097.